Market Risers: Allergy Therapeutics, AstraZeneca, Bunzl

Broker Ratings

Shares of Allergy Therapeutics with EPIC code: LON:AGY has risen 3.55% or 1.25 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The high for the period has peaked at 36.5 dipping to 35. The volume total for shares traded up to this point was 284,040 with the average number of shares traded daily being 506,977. The 52 week high is 40.5 about 5.25 points difference from the previous close and the 52 week low at 12.75 is a variance of 22.5 points. Allergy Therapeutics has a 20 SMA of 36.91 and now the 50 day SMA of 36.08. Market capitalisation is now £234.26m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Allergy Therapeutics being recorded at Tuesday, November 2, 2021 at 12:36:28 PM GMT with the stock price trading at 36.5 GBX.

Stock in AstraZeneca found using EPIC: LON:AZN has gained 1.12% or 102 points during the course of today’s session so far. Investors have stayed positive while the stock has been in play. The period high has peaked at 9275 meanwhile the session low reached 9157.81. Volume total for shares traded at this point reached 308,872 whilst the daily average number of shares exchanged is just 1,901,970. The 52 week high for the shares is 9275 some 137 points different to the previous business close and a 52 week low sitting at 6736 a difference of some 2402 points. AstraZeneca now has a 20 SMA at 8962.84 and now the 50 day moving average now at 8747.35. This puts the market capitalisation now at £144,185.74m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Tuesday, November 2, 2021 at 12:35:26 PM GMT with the stock price trading at 9240 GBX.

Stock in Bunzl with EPIC code: LON:BNZL has risen 1.33% or 36 points throughout today’s trading session so far. Buyers have remained optimistic throughout the session. Range high for the period so far is 2745 and a low of 2690. Volume total for shares traded at this point reached 228,634 with the daily average at 699,886. The 52 week high price for the shares is 2745 about 43 points in difference to the previous days close of business and a 52 week low sitting at 2122 making a difference of 580 points. Bunzl now has a 20 SMA at 2552.61 and now a 50 day MA at 2570.22. This puts the market capitalisation now at £9,260.41m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Bunzl being recorded at Tuesday, November 2, 2021 at 12:31:23 PM GMT with the stock price trading at 2738 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy...

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer.

Bunzl upgrades 2026 guidance after stronger first-half performance

Bunzl says first-half revenue and adjusted operating profit are expected to rise, and it has upgraded its 2026 guidance.

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer.

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival.

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options.

Search